Asia-Pacific (APAC) is witnessing a rising disease burden of liver and renal cancer, driven by chronic viral hepatitis, an aging population, and rising metabolic risk factors such as obesity and diabetes. With rising cancer burden and expanding precision oncology, the APAC positron emission tomography/computed tomography (PET/CT) systems market is forecast to grow at a compound annual growth rate (CAGR) of 10% through 2035, according to GlobalData, a leading intelligence and productivity platform.

GlobalData’s latest report, “Nuclear Imaging Equipment Market Size by Segments, Share, Regulatory, Reimbursement, Installed Base and Forecast to 2036,” reveals that APAC accounted for around 54% of the global PET/CT systems market in 2025.

In September 2026, HKSH Medical Group and United Imaging Healthcare announced the new installation of Hong Kong’s first long-axial PET/CT system uMI Panorama GS at HKSH Cancer Centre. The system features a large axial field-of-view (148 cm) for an increased scanning area, improved sensitivity, reduced image stitching, and enhanced identification and tracking of small tumors and molecular targets.

Priyanka Chakraborty, Medical Devices Analyst at GlobalData, comments: “The new long-axial PET/CT could strengthen HKSH’s position as a referral center for complex cancer cases because it may improve lesion detection and enable advanced multi-tracer or dynamic imaging protocols in selected patients and research settings. This can help clinicians build more precise treatment plans, especially for early-stage cancers where dual-tracer imaging may reveal anomalies that a single tracer could miss.”

The deployment of the new PET/CT system at HKSH Cancer Centre might increase interest in this technology across the region and serve as a reference case for larger hospitals across mainland China, Singapore, South Korea, Japan, and Australia.

Chakraborty continues: “With the advantage of shorter scan times and lower radiotracer doses, this platform is equipped to handle large patient volumes, both local and foreign. This will be especially helpful to oncology centers aiming for early detection of lesions and the delivery of personalized treatment plans.”

Chakraborty concludes: “Securing a foothold in a top-tier private hospital gives United Imaging Healthcare an opportunity to compete directly with established global suppliers of PET/CT systems. The increased throughput, radiotracer dose efficiency, and improved clinical capabilities of the new total body PET/CT system might drive adoption across the APAC region, though the pace of adoption will be determined by constraints of each individual country in terms of reimbursement policies, staff availability, and radiotracer supply networks.”